New York, January 30, 2026, 05:31 EST — Premarket
- Shares of VivoSim Labs surged in pre-market trading following news of an expansion into Asia
- As drugmakers seek quicker safety indicators, the company is advancing human-cell testing.
- Traders are closely monitoring if the move sticks through the regular session and the February results.
VivoSim Labs (VIVS) shares surged in premarket action Friday, more than doubling on news of fresh distributor deals in Korea and China. The stock jumped 111.8% to $3.60, compared with Thursday’s close at $1.70. 1
The shift underscores growing investor interest in “New Approach Methodologies,” or NAMs — lab techniques designed to forecast drug behavior in humans without relying solely on animal testing.
As drug development costs soar and late-stage flops hit hard, companies are pushing for earlier safety readouts. For smaller players like VivoSim, even one distribution headline can send shares tumbling or soaring.
VivoSim announced it has appointed JCBio as an authorized distributor in Korea and Tekon Biotech in China for its NAMKind toxicology services focused on liver and small intestine. The company kept financial details under wraps but highlighted a 30-day turnaround per compound. “Global demand for human-relevant toxicology is shooting up,” said Chief Commercial Officer Tony Lialin. Tekon Biotech President Sanger Chang noted that Chinese clients are “increasingly concerned about late-stage clinical failures, particularly regarding liver safety.” 2
The company offers testing using three-dimensional human tissue models, zeroing in on liver and intestinal safety signals — those critical red flags that can halt a drug program before expensive trials begin. It operates within the wider preclinical services field, largely controlled by big contract research firms, though VivoSim’s approach is more focused and specialized.
Traders are watching closely to see if the premarket surge holds beyond today. Liquidity plays a key role—early gains in lightly traded stocks often vanish quickly once the market opens and larger orders come into play.
A separate SEC filing revealed that director Douglas Jay Cohen was granted 15,000 restricted stock units in an equity award dated Jan. 27, set to vest either next year or at the following annual meeting. 3
The downside is clear-cut: distributor agreements don’t ensure orders, and schedules can slip if local clients drag their feet or if the work fails to turn into steady repeat business. A sharp premarket jump might also trigger profit-taking, particularly in microcaps.
The key now is if VivoSim can turn the announcement into actual customer traction, and if the stock manages to sustain its gains when regular trading kicks in. Eyes will also be on the next earnings report, due around Feb. 18, looking for any early revenue from this new channel. 4
